Neuromuscular Blockade: Agents, Dosing, Monitoring, and Reversal
Rapid Sequence Induction (RSI)
For RSI, use succinylcholine 1-2 mg/kg or rocuronium 0.9-1.2 mg/kg as the first-line rapid-onset neuromuscular blocking agent, with succinylcholine remaining the preferred choice when no contraindications exist. 1, 2
Agent Selection for RSI
Succinylcholine is the gold standard for RSI due to fastest onset (45-60 seconds) and shortest duration 2
Rocuronium is the alternative when succinylcholine is contraindicated 1, 2, 3
Critical Contraindications to Succinylcholine
Succinylcholine is absolutely contraindicated in the following high-risk situations: 2
- Primary muscle damage (myopathies, myotonia) - causes generalized contraction with rhabdomyolysis 2
- Upregulation of nicotinic acetylcholine receptors: 2
- Chronic motor neuron damage
- Extensive/deep burns (>24-48 hours post-injury)
- Prolonged critical illness
- Denervation syndromes
- Risk: life-threatening hyperkalemia
- History of malignant hyperthermia 4
- Known allergy to succinylcholine 5
Routine Surgical Neuromuscular Blockade
Initial Dosing for Non-Emergent Intubation
For routine intubation, rocuronium 0.6 mg/kg or cisatracurium 0.15-0.2 mg/kg provides adequate conditions with predictable duration. 1, 6
Rocuronium (Intermediate-Acting)
Cisatracurium (Intermediate-Acting, Organ-Independent Elimination)
- Adult intubating dose: 0.15-0.2 mg/kg IV over 5-10 seconds 6
- Pediatric (2-12 years): 0.1-0.15 mg/kg 6
- Infant (1-23 months): 0.15 mg/kg 6
Vecuronium (Intermediate-Acting)
Maintenance Dosing During Surgery
Administer maintenance doses based on quantitative neuromuscular monitoring, not fixed time intervals. 1, 7
- Rocuronium maintenance: 0.1-0.2 mg/kg when TOF shows 2 responses 2
- Cisatracurium maintenance: 0.03 mg/kg sustains blockade for ~20 minutes 6
Continuous Infusion Dosing
- Cisatracurium infusion: 1-2 mcg/kg/min after initial bolus 6
- Rocuronium infusion: 10-12 mcg/kg/min 2
- Adjust rate based on TOF monitoring to maintain 1-2 twitches 2, 6
Mandatory Quantitative Neuromuscular Monitoring
Quantitative train-of-four (TOF) monitoring at the adductor pollicis muscle is mandatory before, during, and after neuromuscular blockade to guide dosing and ensure adequate reversal (TOF ratio ≥0.9) before extubation. 1, 7
Monitoring Requirements
- Site: Adductor pollicis muscle (most reliable) 1, 7
- Method: Acceleromyography or electromyography (quantitative, not qualitative) 7
- Target for extubation: TOF ratio ≥0.9 1, 7
- Frequency: Continuous monitoring after reversal agent administration to detect recurarization 2, 7
Clinical Significance
- Residual neuromuscular blockade (TOF <0.9) increases: 7
- Postoperative morbidity and mortality within 24 hours
- Critical respiratory events in recovery
- Risk of postoperative pneumonia
- Pharyngeal muscle dysfunction
- Delayed discharge from recovery room
Reversal of Neuromuscular Blockade
Agent Selection Algorithm
The choice of reversal agent depends entirely on which neuromuscular blocker was used: 7
For Aminosteroidal Agents (Rocuronium, Vecuronium)
Sugammadex is strongly preferred over neostigmine due to superior safety, efficacy, and reduced complications. 2, 7
For Benzylisoquinoline Agents (Atracurium, Cisatracurium)
Neostigmine 0.04 mg/kg plus anticholinergic (atropine 0.02 mg/kg or glycopyrrolate 10 mcg/kg) is required. 7, 8
Sugammadex Dosing Algorithm (Rocuronium/Vecuronium Only)
Sugammadex dose must be determined by quantitative assessment of blockade depth—underdosing causes recurarization. 2, 7
| Depth of Blockade | Sugammadex Dose | Time to TOF ≥0.9 |
|---|---|---|
| Very moderate (TOF ratio ~0.5) | 0.22 mg/kg | <5 minutes [2] |
| Moderate (4 TOF responses visible) | 1.0 mg/kg (standard) | <5 minutes [2,7] |
| Moderate (4 TOF responses) - slower option | 0.5 mg/kg | ~10 minutes [2] |
| Moderate (2 TOF responses) | ≥2.0 mg/kg | <5 minutes [2,7] |
| Deep blockade (PTC 1-2, no TOF) | 4.0 mg/kg | 2-5 minutes [2,7] |
| Very deep/immediate reversal (PTC 0, <3 min post-dose) | 8.0 mg/kg | 3-5 minutes [2,7] |
Critical Sugammadex Considerations
- Calculate dose based on ideal body weight, not actual body weight 7
- Efficacy decreased in: 2, 7
- Elderly patients (may need higher doses)
- Severe renal failure (CrCl <30 mL/min) - especially for deep blockade reversal
- Continue monitoring after administration to detect recurarization 2, 7
- Inadequate dosing is the primary cause of recurarization 2
Clinical Superiority of Sugammadex
- Reduces bradycardia incidence by 84% vs neostigmine (RR 0.16; NNT=14) 7
- Reduces residual paralysis signs by 60% (RR 0.40; NNT=13) 7
- Lower risk of postoperative pulmonary complications vs neostigmine 7
- More predictable reversal in critically ill patients 7
Neostigmine Dosing Algorithm (Atracurium/Cisatracurium Only)
Neostigmine can only reverse moderate blockade (≥4 TOF responses present)—it is completely ineffective for deep blockade. 2, 7, 8
Dosing Protocol
Maximum total dose: 0.07 mg/kg or 5 mg total (whichever is less) 8
For very shallow blockade (TOF ratio 0.4-0.6): Consider reducing neostigmine to 0.02 mg/kg 2
Mandatory Anticholinergic Co-Administration
An anticholinergic agent (atropine or glycopyrrolate) must be administered prior to or concomitantly with neostigmine to prevent bradycardia. 1, 8
Neostigmine Contraindications and Cautions
- Use with extreme caution in: 8
- Coronary artery disease
- Cardiac arrhythmias
- Recent acute coronary syndrome
- Myasthenia gravis
- Contraindicated in: 8
- Peritonitis
- Mechanical intestinal/urinary obstruction
- Known hypersensitivity
Special Populations and Dose Adjustments
Elderly Patients
- Slower onset of blockade - extend interval between NMB administration and intubation attempt 1
- Sugammadex efficacy decreased - may require higher doses 2, 7
- No initial dose adjustment needed for cisatracurium or rocuronium 1, 6
Renal Dysfunction
- Slower onset of blockade - extend interval between NMB administration and intubation attempt 1
- Cisatracurium preferred due to organ-independent (Hofmann) elimination 6
- Sugammadex efficacy significantly decreased in severe renal failure (CrCl <30 mL/min), especially for deep blockade 2, 7
Myasthenia Gravis
Patients with myasthenia gravis require 50-75% dose reduction of non-depolarizing agents and mandatory quantitative monitoring. 2, 9
- Succinylcholine: Paradoxical resistance (requires higher doses) - generally avoided 2, 9
- Non-depolarizing agents: Increased sensitivity and prolonged duration 2, 9
- Baseline TOF <0.9: Indicates greater sensitivity - further dose reduction required 2, 9
- Reversal: Sugammadex preferred over neostigmine 9
- Monitoring: Quantitative TOF monitoring mandatory 2, 9
Obese Patients
- Dose based on ideal body weight for sugammadex 7
- Initial NMB dosing: Use ideal body weight for most agents 2
Pediatric Patients
- Rapid-onset agent mandatory for RSI (same as adults) 2
- Succinylcholine remains first-line for pediatric RSI with age-specific dosing 2
- Rocuronium alternative: >0.9 mg/kg when succinylcholine contraindicated 2
- Residual blockade frequency: 28% in children receiving muscle relaxants 2
- Monitoring mandatory in all pediatric cases 2
Interaction with Volatile Anesthetics
Isoflurane and enflurane at 1.25 MAC prolong the duration of neuromuscular blockade—reduce maintenance doses or extend dosing intervals. 6
- Initial dose: No adjustment needed if NMB given shortly after volatile agent initiation 6
- After 15-30 minutes of volatile exposure: Minimal effect on initial dose 6
- During prolonged surgery: Less frequent or lower maintenance doses required 6
- Propofol anesthesia: No dose adjustment needed 6
Critical Pitfalls to Avoid
Administering neostigmine when <4 TOF responses present - completely ineffective and causes cholinergic toxicity 2, 7
Underdosing sugammadex for depth of blockade - primary cause of recurarization 2, 7
Discontinuing monitoring after reversal - misses late recurarization 2, 7
Using succinylcholine in contraindicated conditions - risk of fatal hyperkalemia or rhabdomyolysis 2
Extubating before TOF ratio ≥0.9 confirmed - increases respiratory complications and mortality 1, 7
Failing to co-administer anticholinergic with neostigmine - causes severe bradycardia 1, 8
Using clinical assessment alone without quantitative monitoring - inadequate for detecting residual blockade 1, 7